Endonuclease IV mutants and their applications
By performing amino acid mutations at specific sites of endonuclease IV, it improves its soluble expression in host cells, solving the problem of low expression of wild-type endonuclease IV, and achieving mass production of oligonucleotides economy and efficiency.
Patent Information
- Application Number
- CN202311670481.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-07
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-12-07
AI Technical Summary
The soluble expression of wild-type endonuclease IV in the E. coli expression system is relatively low, resulting in high cost of batch preparation of oligonucleotides and cannot meet the needs of mass production.
By mutation at specific amino acid sites of endonuclease IV, endonuclease IV mutants, such as pfIV1, pfIV2, and pfIV3, are designed to increase their soluble expression in host cells while maintaining or increasing the enzyme's active.
The expression amount of mutants can be increased by at least 1 times, or even 3 times, reducing the cost of batch preparation of oligonucleotides and meeting the needs of mass production of oligonucleotides.
Smart Images

Figure CN117821422B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a nuclease IV mutant, a gene encoding the same, an expression vector comprising the gene, a host cell comprising the gene or the expression vector, a method for producing a target oligonucleotide using the nuclease IV mutant, and a kit comprising the nuclease IV mutant. Background Art
[0002] Enzymatic cleavage of single-stranded DNA is a rapid and environmentally friendly method for obtaining target oligonucleotides. This method requires the use of two specific active enzymes for catalysis. The basic principle is: using uracil-DNA glycosylase (UDG) to specifically recognize uracil nucleotides in single-stranded DNA, and then removing the glycosidic bond between uracil and deoxypentose in the uracil nucleotide to form an apurinic or apyrimidinic (AP) site; a specific type of apurinic pyrimidinic site endonuclease (AP sites endonuclease, AP Endonuclease) recognizes the AP site on the single-stranded DNA and cuts the phosphodiester bond at the site.
[0003] At present, the nuclease IV (pfIV) from Pyrococcus furiosus has been reported to be able to better recognize and cut single-stranded DNA. However, in actual technical practice, wild-type pfIV is usually isolated and obtained in large quantities through heterologous expression using an Escherichia coli expression system, but its soluble expression level is low and the separation cost is high, which increases the cost level of downstream oligonucleotide batch preparation and cannot meet the needs of oligonucleotide batch production.
[0004] Therefore, how to increase the soluble expression level of endonuclease IV without reducing its activity is an urgent problem to be solved in this field. Summary of the invention
[0005] In view of this, the present invention provides a nuclease IV mutant to increase the soluble expression level of the nuclease IV without reducing its activity.
[0006] Therefore, according to the first aspect of the present invention, a nuclease IV mutant is provided, wherein the nuclease IV mutant comprises mutations at one or more of the following positions compared to the wild-type nuclease as shown in SEQ ID NO: 1: Y58, K61, K82, E83, K116, E171, R135, D139, K161, N205, E226, R231, E236, K253 and I281.
[0007] According to a second aspect of the present invention, there is provided an isolated gene encoding the endonuclease IV mutant of the first aspect of the present invention.
[0008] According to the third aspect of the present invention, there is provided an expression vector comprising the gene of the second aspect of the present invention.
[0009] According to the fourth aspect of the present invention, a host cell is provided, comprising the gene of the second aspect of the present invention or the expression vector of the third aspect of the present invention.
[0010] According to a fifth aspect of the present invention, there is provided a method for producing a target oligonucleotide, the method comprising the step of cleaving single-stranded DNA using the endonuclease IV mutant of the first aspect of the present invention.
[0011] According to a sixth aspect of the present invention, there is provided a kit comprising the endonuclease IV mutant of the first aspect of the present invention, optionally uracil glycosidase, and instructions for use.
[0012] The soluble expression amount of the endonuclease IV mutant provided by the present invention in the host cell is further improved relative to the wild-type endonuclease IV, while its activity does not decrease, which makes it possible to reduce the cost of batch preparation and meet the needs of batch production of oligonucleotides. A large number of experiments have shown that compared with the wild-type endonuclease IV, the expression amount of the endonuclease IV mutant provided by the present invention can be increased by at least nearly 1 times, and even more than 3 times. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments are briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention, and for ordinary technicians in this field, other implementation schemes can be obtained based on these drawings without creative work.
[0014] Figure 1 The expression results of wild-type pfIV enzyme and its mutants are shown, where the BSA concentration gradients are 1: 0.05 mg / ml; 2: 0.10 mg / ml; 3: 0.20 mg / ml; 4: 0.40 mg / ml; 5: 0.80 mg / ml; 6: 1.00 mg / ml; 7: 2.00 mg / ml; 8: 4.00 mg / ml, M represents the protein molecular weight in kD, and the sizes from bottom to top are 14.4, 18.4, 25, 35, 45, 66, 95, WT represents wild-type pfIV, IV1, IV2, IV3 correspond to pfIV1, pfIV2, pfIV3, respectively.
[0015] Figure 2 The activity detection results of the pfIV1 mutant are shown, wherein WT represents wild-type pfIV, IV1, IV2, and IV3 correspond to pfIV1, pfIV2, and pfIV3, respectively, and the arrows indicate the products. DETAILED DESCRIPTION
[0016] The present invention will be described clearly and completely below in conjunction with the embodiments and drawings of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all of the embodiments. All other embodiments that can be obtained by those of ordinary skill in the art based on the embodiments of the present invention belong to the scope of protection of the present invention.
[0017] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0018] The term "mutant" herein mainly refers to a mutant protein produced by a mutation in the amino acid at one or more positions relative to the wild-type protein.
[0019] The term "expression vector" refers to a nucleic acid delivery vehicle into which a nucleotide sequence encoding a protein can be inserted and the protein can be expressed in a suitable host cell. The expression vector can express the genetic material elements it carries in the host cell by transforming, transducing or transfecting the host cell. The types of expression vectors include bacterial plasmids, lentiviral vectors, etc., which are well known in the art. In addition to the origin of replication, the expression vector may also contain marker genes and other translation control elements.
[0020] The term "host cell" refers to a cell that provides a place for the target protein encoding nucleic acid sequence to express the target protein therein. There is no particular limitation on the method by which the target protein encoding nucleic acid sequence enters the host cell, and it may be, for example, direct uptake, transduction, transfection, or other methods known in the art. The exogenous polynucleotide may be maintained as a non-integrated vector such as a plasmid or may be integrated into the host genome. The host cell may be a prokaryotic cell or a eukaryotic cell.
[0021] "Soluble expression" means that the target protein is expressed in a soluble form in the expression system.
[0022] As known to those skilled in the art, wild-type pfIV can better recognize the AP site on single-stranded DNA and cleave the phosphodiester bond at the site. However, the soluble expression of wild-type pfIV is low, and the separation cost is high, which leads to a series of problems such as high batch preparation cost of downstream oligonucleotides and failure to meet the batch production of oligonucleotides.
[0023] In order to solve the problems existing in the prior art, the present invention aims to provide a nuclease IV mutant, whose soluble expression level in host cells is further improved compared with the wild-type pfIV, while its activity is not decreased, thereby reducing the cost of batch preparation and meeting the needs of batch production of oligonucleotides.
[0024] Therefore, according to the first aspect of the present invention, a nuclease IV mutant is provided, wherein the nuclease IV mutant comprises mutations at one or more of the following positions compared to the wild-type nuclease as shown in SEQ ID NO: 1: Y58, K61, K82, E83, K116, E171, R135, D139, K161, N205, E226, R231, E236, K253 and I281.
[0025] It will be appreciated that in the above alphanumeric combinations, letters represent amino acids and numbers represent the position of the amino acids in the sequence. Amino acids are usually represented by single letters and three-letter abbreviations known in the art. For example, alanine can be represented by Ala or A, glycine can be represented by Gly or G, valine can be represented by Val or V, leucine can be represented by Leu or L, isoleucine can be represented by Ile or I, proline can be represented by Pro or P, phenylalanine can be represented by Phe or F, tyrosine can be represented by Tyr or Y, tryptophan can be represented by Trp or W, serine can be represented by Ser or S, threonine can be represented by Thr or T, cysteine can be represented by Cys or C, methionine can be represented by Met or M, asparagine can be represented by Asn or N, glutamine can be represented by Gln or Q, aspartic acid can be represented by Asp or D, glutamic acid can be represented by Glu or E, lysine can be represented by Lys or K, arginine can be represented by Arg or R, and histidine can be represented by His or H.
[0026] In some embodiments, the endonuclease IV mutant comprises any one or more of the following mutations: Y58E, K61E, K82P, E83S, K116G, R135K, D139E, K161D, E171S, N205K, E226D, R231K, E236K, K253D, and I281V.
[0027] In one embodiment, the endonuclease IV mutant comprises the following mutations: Y58E, K61E, K82P, E83S, R135K, D139E, K161D, N205K, E236K and I281V, which mutant is referred to herein as "pfIV1".
[0028] In one embodiment, the endonuclease IV mutant comprises the following mutations: Y58E, K61E, K82P, E83S, K116G, E171S, N205K, E236K, K253D and I281V, which mutant is referred to herein as "pfIV2".
[0029] In one embodiment, the endonuclease IV mutant comprises the following mutations: Y58E, K61E, K82P, E83S, R135K, D139E, K161D, N205K, E226D, R231K and E236K, referred to herein as "pfIV3".
[0030] According to a second aspect of the present invention, there is provided an isolated gene encoding the endonuclease IV mutant of the first aspect of the present invention.
[0031] In one embodiment, the nucleic acid sequence of the gene is shown in any one of SEQ ID NOs: 5-8.
[0032] According to the third aspect of the present invention, there is provided an expression vector comprising the gene of the second aspect of the present invention.
[0033] In some embodiments, the expression vector is a plasmid such as pET28a, pET22b, pET32a, pET50b, a phage particle, or a viral vector. Of course, the expression vector may also be other expression vectors known to those of ordinary skill in the art that are suitable for the present invention, and the present invention is not limited thereto.
[0034] According to the fourth aspect of the present invention, a host cell is provided, comprising the gene of the second aspect of the present invention or the expression vector of the third aspect of the present invention.
[0035] In some embodiments, the host cell is a prokaryotic cell, for example, an Escherichia coli cell, such as BL21 (DE3), BL21 (DE3) plys, Rosseta (DE3), Origami, or a eukaryotic cell, such as yeast. Of course, the host cell may also be other host cells known to those of ordinary skill in the art that are suitable for the present invention, and the present invention is not limited thereto.
[0036] According to a fifth aspect of the present invention, there is provided a method for producing a target oligonucleotide, the method comprising the step of cleaving single-stranded DNA using the endonuclease IV mutant of the first aspect of the present invention.
[0037] In some embodiments, the method comprises: 1) using uracil glycosidase to remove the glycosidic bond between uracil and deoxypentose in the uracil nucleotide of the single-stranded DNA to form an apurinic pyrimidine base site; 2) using the nuclease IV mutant described in the first aspect of the present invention to recognize the apurinic pyrimidine base site and cut the phosphodiester bond of the site to obtain the target oligonucleotide.
[0038] According to a sixth aspect of the present invention, there is provided a kit comprising the endonuclease IV mutant of the first aspect of the present invention, optionally uracil glycosidase, and instructions for use.
[0039] The soluble expression amount of the endonuclease IV mutant provided by the present invention in the host cell is further improved relative to the wild-type endonuclease IV, while its activity does not decrease, which makes it possible to reduce the cost of batch preparation and meet the needs of batch production of oligonucleotides. A large number of experiments have shown that compared with the wild-type endonuclease IV, the expression amount of the endonuclease IV mutant provided by the present invention can be increased by at least nearly 1 times, and even more than 3 times.
[0040] The present invention is described in more detail below in conjunction with the accompanying drawings and examples, which are only preferred embodiments of the present invention and are not intended to limit the present invention. Unless otherwise specified, all raw materials and reagents of the present invention are those from the conventional market.
[0041] Example
[0042] Example 1: Design of pfIV mutants
[0043] In order to further increase the soluble expression of pfIV enzyme, the present invention analyzes the three-dimensional structure of wild-type pfIV by PymoL software, obtains polar amino acid residues with a relative solvent accessible surface area of less than 30% (such as several of D, E, K, R, N, Q, Y, H, S and T) and hydrophobic amino acid residues with a relative solvent accessible surface area of more than 30% (several of I, L, F and W), and removes the residues near the active center. Then, ProteinMPNN was used to design protein sequences and mutations were designed for the amino acid residues selected above.
[0044] In the present invention, pfIV includes the following specific mutation designs: After screening, the sites for mutation design were determined to be Y58, K61, K82, E83, K116, E171, R135, D139, K161, N205, E226, R231, E236, K253 and I281. The combinations obtained by design are shown in Table 1.
[0045] Table 1 Mutation site combinations
[0046]
[0047] The sequence of wild-type pfIV (Genbak: GenBank: AAL80382.1, uniprot: Q8U437) SEQ ID NO: 1 is shown below:
[0048] MFKIDRLRFGTAGIPLSTPKPSTIAGIERVRELGLDAMELEFVRGVNIRPELAKKIKYVA
[0049] KKNDVVLTAHAPYYINLNAKEKEKVESSKRRIIQSAERLYEAGGWSVVFHAGYYLKE
[0050] HPEKVYQKIESTLKDIERELKDRGIEVWLRPELTGKPTQFGDLKELIKLSQNLELVLPAI
[0051] DFAHAHARNKGKCNSEEEWREMLALIENELGREALDNMHIHISGIEYTEKGEKRHLNL
[0052] EESDLKWEDLLKVLKEFKVKGVVISESPNIEGDALLMKKKWEELKI
[0053] The sequence of endonuclease IV mutant 1 (pfIV1) SEQ ID NO: 2 is as follows: MFKIDRLRFGTAGIPLSTPKPSTIAGIERVRELGLDAMELEFVRGVNIRPELAKKIKEVAEKNDVVLTAHAPYYINLNAKEPSKVESSKRRIIQSAERLYEAGGWSVVFHAGYYLKEHPEKVYQKIESTLKDIEKELKERGIEVWLRPELTGKPTQFGDLDELIKLSQNLELVLPAIDFAHAHARNKGKCNSEEEWREMLALIEKELGREALDNMHIHISGIEYTEKGEKRHLNLKESDLKWEDLLKVLKEFKVKGVVISESPNIEGDALLMKKKWEELKV
[0054] The sequence of endonuclease IV mutant 2 (pfIV2) SEQ ID NO: 3 is as follows: MFKIDRLRFGTAGIPLSTPKPSTIAGIERVRELGLDAMELEFVRGVNIRPELAKKIKEVAEKNDVVLTAHAPYYINLNAKEPSKVESSKRRIIQSAERLYEAGGWSVVFHAGYYLGEHPEKVYQKIESTLKDIEKELKERGIEVWLRPELTGKPTQFGDLDELIKLSQNLSLVLPAIDFAHAHARNKGKCNSEEEWREMLALIEKELGREALDNMHIHISGIEYTEKGEKRHLNLKESDLKWEDLLKVLKEFDVKGVVISESPNIEGDALLMKKKWEELKV
[0055] The sequence of endonuclease IV mutant 3 (pfIV3) SEQ ID NO: 4 is as follows: MFKIDRLRFGTAGIPLSTPKPSTIAGIERVRELGLDAMELEFVRGVNIRPELAKKIKEVAEKNDVVLTAHAPYYINLNAKEPSKVESSKRRIIQSAERLYEAGGWSVVFHAGYYLKEHPEKVYQKIESTLKDIEKELKERGIEVWLRPELTGKPTQFGDLDELIKLSQNLELVLPAIDFAHAHARNKGKCNSEEEWREMLALIEKELGREALDNMHIHISGIEYTDKGEKKHLNLKESDLKWEDLLKVLKEFKVKGVVISESPNIEGDALLMKKKWEELKI
[0056] The nucleic acid sequence of wild-type pfIV, SEQ ID NO: 5, is as follows: ATGTTCAAAATCGACCGTCTGCGTTTCGGTACCGCTGGTATCCCGCTGTCTACCCCGAAACCGTCTACCATCGCTGGTATCGAACGTGTTCGTGAACTGGGTCTGGACGCTATGGAACTGGAATTCGTTCGTGGTGTTAACATCCGTCCGGAACTGGCTAAAAAAATCAAATACGTTGCTAAAAAAAACGACGTTGTTCTGACCGCTCACGCTCCGTACTACATCAACCTGAACGCTAAAGAAAAAGAAAAAGTTGAATCTTCTAAACGTCGTATCATCCAGTCTGCTGAACGTCTGTACGAAGCTGGTGGTTGGTCTGTTGTTTTCCACGCTGGTTACTACCTGAAAGAACACCCGGAAAAAGTTTACCAGAAAATCGAATCTACCCTGAAAGACATCGAACGTGAACTGAAAGACCGTGGTATCGAAGTTTGGCTGCGTCCGGAACTGACCGGTAAACCGACCCAGTTCGGTGACCTGAAAGAACTGATCAAACTGTCTCAGAACCTGGAACTGGTTCTGCCGGCTATCGACTTCGCTCACGCTCACGCTCGTAACAAAGGTAAATGCAACTCTGAAGAAGAATGGCGTGAAATGCTGGCTCTGATCGAAAACGAACTGGGTCGTGAAGCTCTGGACAACATGCACATCCACATCTCTGGTATCGAATACACCGAAAAAGGTGAAAAACGTCACCTGAACCTGGAAGAATCTGACCTGAAATGGGAAGACCTGCTGAAAGTTCTGAAAGAATTCAAAGTTAAAGGTGTTGTTATCTCTGAATCTCCGAACATCGAAGGTGACGCTCTGCTGATGAAAAAAAAATGGGAAGAACTGAAAATCTAA
[0057] The nucleotide sequence of endonuclease IV mutant 1 (pfIV1), SEQ ID NO: 6, is as follows:
[0058] ATGTTCAAAATCGACCGTCTGCGTTTCGGTACCGCTGGTATCCCGCTGTCTACCCCG
[0059] AAACCGTCTACCATCGCTGGTATCGAACGTGTTCGTGAACTGGGTCTGGACGCTATG
[0060] GAACTGGAATTCGTTCGTGGTGTTAACATCCGTCCGGAACTGGCTAAAAAAATCAA
[0061] AGAAGTTGCTGAAAAAAACGACGTTGTTCTGACCGCTCACGCTCCGTACTACATCA
[0062] ACCTGAACGCTAAAGAACCGTCTAAAGTTGAATCTTCTAAACGTCGTATCATCCAGT
[0063] CTGCTGAACGTCTGTACGAAGCTGGTGGTTGGTCTGTTGTTTTCCACGCTGGTTACT
[0064] ACCTGAAAGAACACCCGGAAAAAGTTTACCAGAAAATCGAATCTACCCTGAAAGA
[0065] CATCGAAAAAGAACTGAAAGAACGTGGTATCGAAGTTTGGCTGCGTCCGGAACTG
[0066] ACCGGTAAACCGACCCAGTTCGGTGACCTGGACGAACTGATCAAACTGTCTCAGAA
[0067] CCTGGAACTGGTTCTGCCGGCTATCGACTTCGCTCACGCTCACGCTCGTAACAAAG
[0068] GTAAATGCAACTCTGAAGAAGAATGGCGTGAAATGCTGGCTCTGATCGAAAAAGAA
[0069] CTGGGTCGTGAAGCTCTGGACAACATGCACATCCACATCTCTGGTATCGAATACACC
[0070] GAAAAAGGTGAAAAACGTCACCTGAACCTGAAAGAATCTGACCTGAAATGGGAAG
[0071] ACCTGCTGAAAGTTCTGAAAGAATTCAAAGTTAAAGGTGTTGTTATCTCTGAATCTC
[0072] CGAACATCGAAGGTGACGCTCTGCTGATGAAAAAAAAATGGGAAGAACTGAAAGT
[0073] TTAA
[0074] The nucleotide sequence of endonuclease IV mutant 2 (pfIV1), SEQ ID NO: 7, is shown below:
[0075] ATGTTCAAAATCGACCGTCTGCGTTTCGGTACCGCTGGTATCCCGCTGTCTACCCCG
[0076] AAACCGTCTACCATCGCTGGTATCGAACGTGTTCGTGAACTGGGTCTGGACGCTATG
[0077] GAACTGGAATTCGTTCGTGGTGTTAACATCCGTCCGGAACTGGCTAAAAAAATCAA
[0078] AGAAGTTGCTGAAAAAAACGACGTTGTTCTGACCGCTCACGCTCCGTACTACATCA
[0079] ACCTGAACGCTAAAGAACCGTCTAAAGTTGAATCTTCTAAACGTCGTATCATCCAGT
[0080] CTGCTGAACGTCTGTACGAAGCTGGTGGTTGGTCTGTTGTTTTCCACGCTGGTTACT
[0081] ACCTGGGTGAACACCCGGAAAAAGTTTACCAGAAAATCGAATCTACCCTGAAAGA
[0082] CATCGAAAAAGAACTGAAAGAACGTGGTATCGAAGTTTGGCTGCGTCCGGAACTG
[0083] ACCGGTAAACCGACCCAGTTCGGTGACCTGGACGAACTGATCAAACTGTCTCAGAA
[0084] CCTGTCTCTGGTTCTGCCGGCTATCGACTTCGCTCACGCTCACGCTCGTAACAAAGG
[0085] TAAATGCAACTCTGAAGAAGAATGGCGTGAAATGCTGGCTCTGATCGAAAAAGAAC
[0086] TGGGTCGTGAAGCTCTGGACAACATGCACATCCACATCTCTGGTATCGAATACACCG
[0087] AAAAAGGTGAAAAACGTCACCTGAACCTGAAAGAATCTGACCTGAAATGGGAAGA
[0088] CCTGCTGAAAGTTCTGAAAGAATTCGACGTTAAAGGTGTTGTTATCTCTGAATCTCC
[0089] GAACATCGAAGGTGACGCTCTGCTGATGAAAAAAAAATGGGAAGAACTGAAAGTT
[0090] TAA
[0091] The nucleotide sequence of endonuclease IV mutant 3 (pfIV1), SEQ ID NO: 8, is shown below:
[0092] ATGTTCAAAATCGACCGTCTGCGTTTCGGTACCGCTGGTATCCCGCTGTCTACCCCG
[0093] AAACCGTCTACCATCGCTGGTATCGAACGTGTTCGTGAACTGGGTCTGGACGCTATG
[0094] GAACTGGAATTCGTTCGTGGTGTTAACATCCGTCCGGAACTGGCTAAAAAAATCAA
[0095] AGAAGTTGCTGAAAAAAACGACGTTGTTCTGACCGCTCACGCTCCGTACTACATCA
[0096] ACCTGAACGCTAAAGAACCGTCTAAAGTTGAATCTTCTAAACGTCGTATCATCCAGT
[0097] CTGCTGAACGTCTGTACGAAGCTGGTGGTTGGTCTGTTGTTTTCCACGCTGGTTACT
[0098] ACCTGAAAGAACACCCGGAAAGTTTACCAGAAAATCGAATCTACCCTGAAAGA
[0099] CATCGAAGAACTGAAAGAACGTGGTATCGAAGTTTGGCTGCGTCCGGAACTG
[0100] ACCGGTAAACCGACCCAGTTCGGTGACCTGGACGAACTGATCAAACTGTCTCAGAA
[0101] CCTGGAACTGGTTCTGCCGGCTATCGACTTCGCTCACGCTCACGCTCGTAACAAAG
[0102] GTAAATGCAACTCTGAAGAAGAATGGCGTGAAATGCTGGCTCTGATCGAAGAAGAA
[0103] CTGGGTCGTGAAGCTCTGGACAACATGCACATCCACATCTCTGGTATCGAATACACC
[0104] GACAAAGGTGAAAAAAACACCTGAACCTGAAAGAATCTGACCTGAAATGGGAAG
[0105] ACCTGCTGAAAGTTCTGAAAGAATTCAAAGTTAAAGGTGTTGTTATCTCTGAATCTC
[0106] CGAACATCGAAGGTGACGCTCTGCTGATGAAAAAAAAATGGGAAGAACTGAAAAT
[0107] CTAA
[0108] Example 2: Obtaining pfIV mutants
[0109] After the amino acid sequence of the pfIV enzyme was designed, codon optimization was performed using Jcat software to obtain a nucleic acid sequence (SEQ ID NO: 5 to SEQ ID NO: 8), and the nucleic acid sequence was sent to Nanjing Qingke Biotechnology Co., Ltd. for synthesis, wherein the nucleic acid sequence was synthesized into a commercial expression vector pET-28a (Novagen) based on the T7 promoter, and the expression vector contained an operator sequence that responded to IPTG-induced expression.
[0110] Example 3: Expression and purification of pfIV enzyme
[0111] 1) Add wild-type pfIV and its mutants pfIV1, pfIV2, and pfIV3 expression vectors to 100 μL of competent E. coli BL21 (DE3), place on ice for 30 minutes, heat shock at 42°C for 45 seconds, and place on ice for 2 minutes. Then, add 900 μL LB to the E. coli, incubate at 37°C and 220 rpm for 1 hour, and then spread the E. coli on a kanamycin-resistant LB plate and culture at 37°C overnight.
[0112] 2) The bacteria were transferred to 4 mL of LB liquid medium and cultured at 37°C and 180 rpm for 4 h; then 4 mL of the bacterial solution was transferred to 500 mL of LB liquid medium and cultured at 37°C and 160 rpm for another 4 h, then the temperature was lowered to 16°C, the speed was reduced to 140 rpm, IPTG was added at a final concentration of 0.3 mM, and the expression was induced for 20 h.
[0113] 3) Then centrifuge at 3500 rpm for 15 min, collect the cells, weigh them, and subtract the weight of the collection tube to obtain the wet weight of each cell.
[0114] 4) Resuspend the cells in 50 mL of lysis buffer (20 mM Tris-Cl pH 7.6, 250 mM NaCl, 10% glycerol); disrupt the cells using a high-throughput ultrasonic disruptor with a time interval of 10 s, a power of 100%, and a duration of 60 min.
[0115] 5) After ultrasonic disruption, centrifuge at 12000rpm for 30min, collect the supernatant, mix with 100μL Ni-NTA filler (the filler is denickeled by EDTA and re-nickeled), and incubate at 4℃ for 1h. Then, centrifuge at 2500rpm for 1min to collect the filler. Collect the flow-through sample and filler sample for SDS-PAGE. Wash the filler with buffer containing 20mM imidazole, 50mM imidazole and 300mM imidazole in sequence, and collect the wash sample.
[0116] The protein results obtained are as follows Figure 1 As shown, the concentration gradient of BSA bands was used as a reference. Figure 1It can be seen that the wild-type pfIV enzyme and its mutants pfIV1, pfIV2, and pfIV3 can all be well expressed in a soluble manner.
[0117] Example 4: Comparison of soluble expression levels
[0118] The expression levels were compared by SDS-PAGE, and the concentration of the target enzyme was estimated using the BSA band of the concentration gradient as a reference. The comparison results are shown in Table 2. From the results in Table 2, it can be seen that compared with the wild-type pfIV (WT), the expression level of pfIV1 is about 1.74 times that of WT, pfIV2 is about 4.09 times that of WT, and pfIV3 is about 3.41 times that of WT.
[0119] Table 2 Comparison of expression levels of wild-type pfIV and its mutants
[0120]
[0121] Example 5: Activity detection and comparison
[0122] The activity of each pfIV enzyme obtained was detected using a ssDNA chain of uracil nucleotides (5'FAM-GTATTGCCTTTCCTACGACCTCACGC(dU)TAATGAATGAC ACTCAATGCACAT-3'). The 5' end of the ssDNA chain contains a fluorescent labeled FAM group, which is conducive to better observation of the product. The total amount of ssDNA is 200pmol. NEB UDG (Cat. No.: M0372S) was first added to react at 37°C for 5min, inactivated at 50°C for 5min, and then 1μL of the wild-type pfIV enzyme and its mutants pfIV1, pfIV2, and pfIV3 were added at equal concentrations, reacted for 5min, and finally EDTA with a final concentration of 10mM was added to terminate the reaction. The specific reaction system is as follows:
[0123] Table 3 Reaction system 1
[0124]
[0125]
[0126] Table 4 Reaction system 2
[0127] name Addition amount UDG reaction product 24μL Endonuclease IV or its mutants 1μL total 25μL
[0128] Finally, SDS-PAGE was used for electrophoresis at 220 V for 60 min. Figure 2 As shown. Figure 2In the table, CK1 is a negative control without UDG and pfIV; CK2 is a control with only UDG added, which is used to show that the product cannot be produced by UDG alone; the conditional control is a control with only wild-type pfIV and its pfIV mutants but no UDG added, which is used to show that the pfIV mutants alone cannot form products. Figure 2 It can be seen that, combined with various controls, the product amounts of mutants pfIV1, pfIV1, and pfIV3 did not decrease compared with WT, indicating that the activity did not decrease after the soluble expression level was increased.
Claims
1. A nuclease IV mutant, wherein: The sequence of the endonuclease IV mutant is SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO:
4.
2. An isolated gene encoding the endonuclease IV mutant of claim 1.
3. The isolated gene according to claim 2, wherein The nucleic acid sequence of the gene is shown in any one of SEQ ID NOs: 6-8.
4. An expression vector comprising the isolated gene according to claim 2 or 3.
5. The expression vector according to claim 4, wherein The expression vector is a plasmid, a phage particle, or a viral vector.
6. The expression vector according to claim 5, wherein The plasmids are pET28a, pET22b, pET32a, and pET50b.
7. A host cell comprising the isolated gene according to claim 2 or 3 or the expression vector according to any one of claims 4 to 6.
8. The host cell according to claim 7, wherein The host cell is a prokaryotic cell or a eukaryotic cell.
9. The host cell according to claim 8, wherein The prokaryotic cells are Escherichia coli cells.
10. The host cell according to claim 9, wherein The Escherichia coli cells are BL21(DE3), BL21(DE3)plys, Rosseta(DE3), and Origami.
11. The host cell according to claim 8, wherein The eukaryotic cell is a yeast cell. 12 . A method for producing a target oligonucleotide, the method comprising the step of cleaving single-stranded DNA using the endonuclease IV mutant according to claim 1 .
13. The method according to claim 12, comprising: 1) using uracil glycosidase to remove the glycosidic bond between uracil and deoxypentose in the uridine nucleotide of the single-stranded DNA to form a purine-free pyrimidine base site; 2) using the endonuclease IV mutant of claim 1 to recognize the apurine pyrimidine base site and cleave the phosphodiester bond at the site, thereby obtaining the target oligonucleotide.
14. A kit comprising the endonuclease IV mutant of claim 1 and instructions for use.
15. The kit according to claim 14, wherein The kit comprises uracil glycosidase.
